Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 4,544,707 |
|
|||||
| News | - | ||||||
| Day High | 0.1675 | Low High |
|||||
| Day Low | 0.1476 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.00526 | -3.33% | 0.1525 | 10:19:05 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.1629 | 0.1476 | 0.1675 | 0.15776 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 299 | 4,544,707 | US$ 0.155474 | US$ 706,583 | - | 0.1275 - 0.418 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 10:19:00 | 5,000 | US$ 0.1525 | USD |
CytoDyn Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 166.52M | 921.12M | 556.02M | 0 | -79.82M | -0.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CytoDyn (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/06/2024 | 16:17 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 5/06/2024 | 16:16 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 5/06/2024 | 16:09 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/08/2024 | 20:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 3/01/2024 | 16:16 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 3/01/2024 | 16:15 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2/22/2024 | 16:16 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2/21/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 2/15/2024 | 20:00 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
| 2/12/2024 | 16:31 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 1/29/2024 | 16:22 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 1/29/2024 | 07:40 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.24 | 0.315 | 0.1476 | 0.2119989 | 10,279,031 | -0.0875 | -36.46% |
| 1 Month | 0.152 | 0.315 | 0.14 | 0.2082749 | 3,226,874 | 0.0005 | 0.33% |
| 3 Months | 0.1899 | 0.315 | 0.1275 | 0.1852733 | 1,940,524 | -0.0374 | -19.69% |
| 6 Months | 0.2155 | 0.418 | 0.1275 | 0.199456 | 2,872,568 | -0.063 | -29.23% |
| 1 Year | 0.26 | 0.418 | 0.1275 | 0.2017682 | 2,164,514 | -0.1075 | -41.35% |
| 3 Years | 2.03 | 2.54 | 0.1275 | 0.586351 | 2,174,861 | -1.88 | -92.49% |
| 5 Years | 0.391 | 10.01 | 0.1275 | 2.14 | 2,916,174 | -0.2385 | -61.00% |
CytoDyn (QB) Description
| CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. |
